Journal of AdvancedMedical and Dental Sciences Research

Introduction- NAFLD ranges from Simple fatty liver to NASH, Cirrhosis and hepatocellular carcinoma. Identification of patient in early stages provides possibility of disease reversal. Lifestyle modifications+ known to achieve reversal are difficult and have poor compliance. Studies have shown some effects of drugs like pioglitazone, Vitamin E, Omega-3, Metformin and urodeoxycholic acid. There are limited studies of effect of pioglitazone on NAFLD in Patients with Type 2 DM and none in Indian patients as per our literature search. Methodology- Total 150 patients with as per inclusion and exclusion criteria were included in the study & patients were started on pioglitazone therapy. Before starting of therapy, baseline NAFLD score was calculated for each patients. After 6 months therapy with pioglitazone again NAFLD fibrosis score was calculated for every patients. Result- Total 150 patients of NAFLD were given pioglitazone NFS was calculated before & after 6 month. Observations show Male: Female ratio of study subjects 3.5:1. Mean age of study subjects was 53.08 ± 6.94, NAFLD Fibrosis Score significantly decreased after treatment with pioglitazone (p<0.01), There was significant negative correlation between various  anthropometric and biochemical parameters and NAFLD fibrosis score. (p<0.01) Conclusion-The administration of pioglitazone led to metabolic improvement in type II diabetic subjects with NAFLD. NAFLD fibrosis score was very useful non-invasive tool to assess fibrosis in NAFLD in type II diabetic subjects. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone.
Key words: Diabetes, Fatty Liver, Fibrosis Score.

Received: 14 December  2018                                  Revised: 27 December 2018                          Accepted: 28 December 2018
Corresponding author: Dr. Onkar Kakare, Junior Resident, Department of Medicine, D.Y.Patil Medical & Hospital Research Institute, Kolhapur, Maharashtra, India

 This article may be cited as: Kakare O, Sharma S. Effect of Pioglitazone on Non-Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients Using NAFLD Fibrosis Score. J Adv Med Dent Scie Res 2019;7(1):76-85.

Introduction- NAFLD ranges from Simple fatty liver to NASH, Cirrhosis and hepatocellular carcinoma. Identification of patient in early stages provides possibility of disease reversal. Lifestyle modifications+ known to achieve reversal are difficult and have poor compliance. Studies have shown some effects of drugs like pioglitazone, Vitamin E, Omega-3, Metformin and urodeoxycholic acid. There are limited studies of effect of pioglitazone on NAFLD in Patients with Type 2 DM and none in Indian patients as per our literature search. Methodology- Total 150 patients with as per inclusion and exclusion criteria were included in the study & patients were started on pioglitazone therapy. Before starting of therapy, baseline NAFLD score was calculated for each patients. After 6 months therapy with pioglitazone again NAFLD fibrosis score was calculated for every patients. Result- Total 150 patients of NAFLD were given pioglitazone NFS was calculated before & after 6 month. Observations show Male: Female ratio of study subjects 3.5:1. Mean age of study subjects was 53.08 ± 6.94, NAFLD Fibrosis Score significantly decreased after treatment with pioglitazone (p<0.01), There was significant negative correlation between various  anthropometric and biochemical parameters and NAFLD fibrosis score. (p<0.01) Conclusion-The administration of pioglitazone led to metabolic improvement in type II diabetic subjects with NAFLD. NAFLD fibrosis score was very useful non-invasive tool to assess fibrosis in NAFLD in type II diabetic subjects. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone.
Key words: Diabetes, Fatty Liver, Fibrosis Score.

Received: 14 December  2018                                  Revised: 27 December 2018                          Accepted: 28 December 2018
Corresponding author: Dr. Onkar Kakare, Junior Resident, Department of Medicine, D.Y.Patil Medical & Hospital Research Institute, Kolhapur, Maharashtra, India

 This article may be cited as: Kakare O, Sharma S. Effect of Pioglitazone on Non-Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients Using NAFLD Fibrosis Score. J Adv Med Dent Scie Res 2019;7(1):76-85.